While this discrepancy remains unexplained, these findings further indicate that the correlation between PI3K/AKT activation and efficacy of the AKT inhibitors depends on a complex—and as yet only partially understood—specific biological context of each BC subgroup. The gene discussed is PIK3CA; the disease is breast cancer.